pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Monoclonal Antibody · news · pharmadog
← back to Monoclonal Antibody
News · Monoclonal Antibody
785
stories
4d
Lilly signs $5.9B deal with Stipple to unlock oncology targets
fiercebiotech
4d
Summit shares fall as FDA rejects closely watched PD-1/VEGF drug
biopharma dive
4d
J&J pays $2.2B upfront for Ollin, taps Blackstone to fund eye disease trial
biospace
4d
Lilly’s early-stage M&A quest finds $1.5B deal for Calytrix’s blood cancer work
biospace
4d
FDA’s Summit rejection puts PD-1xVEGF class on notice to establish overall survival
biospace
4d
Lilly adds to buyout streak with $1.5B purchase of startup Calytrix
biopharma dive
5d
Biogen inks $411M neurodegeneration pact with protein degrader biotech TrimTech
fiercebiotech
5d
J&J pays $2.2B upfront for Ollin to challenge Roche’s Vabysmo with phase 3 bispecific
fiercebiotech
5d
Lilly secures another myelofibrosis option via $1.5B deal for JPM-founded Calytrix
fiercebiotech
5d
Aclaris drops TSLP program from pipeline after flunking phase 2 eczema test
fiercebiotech
5d
Alzheimer’s field looks beyond amyloid as biopharma converges at CTAD 2026
biospace
5d
Summit's PD-1xVEGF rejected by FDA in lung cancer
biospace
7d
Argenx is spending billions to push beyond Vyvgart
endpoints
7d
AstraZeneca pulls EU filing for antibody as CHMP backs Gazyvaro in lupus
endpoints
7d
Regeneron posts mid-stage POTS data; Kyverna completes CAR-T filing
endpoints
7d
Windward nets $175M IPO, bringing 2026 biotech debuts to 35
biospace
7d
FDA rejects Summit’s ivonescimab, derailing US arrival of much-hyped PD-1xVEGF class
fiercebiotech
7d
Regeneron’s POTS antibody curbs heart rate spikes, teeing up Phase 3 trial
biospace
8d
Rezolute gets an uplift from phase 3 tumor hyperinsulinism win ahead of FDA meeting
fiercebiotech
8d
Marrow extracts $120M series B to advance preclinical blood disease therapy
fiercebiotech
8d
Sanofi-backed Windward hits $225M IPO goal, as Rezera delays listing over ‘market conditions’
fiercebiotech
8d
Regeneron posts positive phase 2 data for baloncibart in nervous system disorder, eyes pivotal trial
fiercebiotech
8d
Windward prices $175M IPO to advance China-licensed lung drugs
biopharma dive
8d
Pfizer snags $1.5B financing from PE firm Blackstone to support Metsera asset
biospace
9d
Pfizer taps Blackstone for up to $1.5B to pave path to GLP-1's obesity launch
fiercebiotech
9d
Why a fresh approach to targeting G protein-coupled receptors could treat a rare eye cancer
fiercebiotech
9d
PepGen shares almost double as DM1 oligonucleotide achieves ‘best in class’ splicing
biospace
9d
AstraZeneca buys vaccine startup; FDA issues GLP-1 safety warning
biopharma dive
9d
VectorY bags $83.5M for antibody gene therapies in neurodegenerative diseases
endpoints
10d
Novartis’ Zolgensma woes, BIO’s China plan, GLP-1s’ new safety warning, FDA’s stacked November
biospace
← prev
page 2 of 27
next →